April 8 (Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Monday. (Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.02 USD | -1.80% | -3.39% | -6.36% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,575 JPY | -0.31% | -1.66% | 8.78B | ||
154.1 USD | -1.88% | -5.28% | 277B | ||
27.02 USD | -1.80% | -3.39% | 1.51B | ||
0.585 USD | -16.43% | -16.43% | 869K | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.36% | 1.51B | |
+16.34% | 79.03B | |
+8.65% | 8.78B | |
-16.33% | 4.83B | |
+51.22% | 4.65B | |
+2.18% | 3.89B | |
+20.51% | 2.34B | |
-26.79% | 2.18B | |
+15.12% | 2.11B | |
-36.56% | 2B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease